Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

GSK PLC closed 23.31% below its 52-week high of £18.24, which the company reached on May 16th.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Blue Trust Inc. lifted its position in GSK plc (NYSE:GSK – Free Report) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,505 shares of the pharmaceutical ...

The FTSE 100 index has started the year well as it surged to a record high. It moved to a high of £8,645, up by over 75% from ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 12.59%, which has investors questioning if this is right time to ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of market volatility.

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...